Peptides as drugs vs research chemicals: the legal distinction

Background

When a peptide is described as a “drug” in the United States, the term carries a precise legal meaning. The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines a drug, in part, as any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or function of the body. A peptide that meets that definition is regulated as a drug regardless of how it is marketed. The U.S. Food and Drug Administration (FDA) outlined the agency’s regulatory perimeter on its compounding landing page, where it noted that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness, or quality of compounded preparations (FDA 2024).

The peptides commonly discussed in clinical and consumer contexts fall into three buckets the FDA distinguishes in published guidance:

1. FDA-approved peptide drugs — products with a New Drug Application (NDA) or Biologics License Application (BLA) and an approved label, such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, octreotide, and goserelin.
2. Compounded peptides — preparations made by licensed pharmacists or outsourcing facilities under sections 503A or 503B of the FD&C Act, using bulk drug substances that are either the subject of an applicable USP/NF monograph, components of an FDA-approved drug, or appear on the FDA’s 503A or 503B bulks lists.
3. Substances marketed as “research chemicals” — products sold online with disclaimers such as “for research use only” or “not for human consumption,” frequently outside the FDA-approved drug supply.

What 503A and 503B describe

Sections 503A and 503B of the FD&C Act describe two distinct compounding pathways. Section 503A applies to traditional compounding by a licensed pharmacist or physician for an identified individual patient pursuant to a valid prescription. Section 503B applies to “outsourcing facilities” that may compound larger quantities, including for office stock, but must comply with current good manufacturing practice (cGMP) and are subject to FDA inspection.

Both pathways require that the bulk drug substance used in compounding satisfy at least one of three criteria the FDA summarized on its bulks-substance reference page: the substance is the subject of a USP or NF monograph, is a component of an FDA-approved drug, or appears on the FDA’s bulks list (FDA 503A bulks page).

The Pharmacy Compounding Advisory Committee (PCAC) is the federal advisory committee that reviews bulk drug substances nominated for the 503A list. The FDA described the committee’s charter as advising the agency “on scientific, technical, and medical issues concerning drug compounding by licensed pharmacists in accordance with section 503A” (FDA PCAC page). PCAC recommendations are non-binding; the FDA is the final decision-maker.

”Research chemicals” and the not-for-human-consumption disclaimer

A separate category of online commerce sells peptides under labels such as “research use only” or “not for human consumption.” STAT News reporting characterized this segment as a regulatory gray zone where vendors avoid both the drug-approval pathway and the dietary-supplement pathway, instead positioning their products as laboratory reagents (STAT News). The legal premise behind the disclaimer is that, absent a claim of human use, the seller is not introducing a drug into interstate commerce.

The FDA has not endorsed that premise. The agency’s enforcement posture, as documented in warning letters cataloged on FDA.gov, has treated intent of use as a factual question that does not turn on the seller’s labeling language. Where the agency has concluded that a peptide product is intended for human use — based on dosing instructions, product claims, or context of sale — it has classified the product as an unapproved new drug.

For consumers, the practical distinction between “compounded peptide” and “research chemical” is whether a licensed pharmacist filled a prescription against a bulk substance that satisfies the 503A criteria, or whether a website sold a vial accompanied by a disclaimer. The two products may contain identical molecules; the legal framework that governs them is not identical.

Why it matters

The PCAC meetings scheduled for July 23 and July 24, 2026 will examine seven peptides nominated for the 503A bulks list. The committee’s recommendations, and the FDA’s subsequent listing decisions, will determine whether licensed pharmacists may continue to compound those substances under the 503A pathway. Substances the FDA declines to add — and that do not otherwise satisfy the monograph or approved-component criteria — would fall outside the legal compounding perimeter, regardless of how they are currently distributed online.

Readers seeking an FDA-approved peptide drug can verify status on the agency’s Drugs@FDA database and the DailyMed label repository.